BioGaia Gastrus Probiotics with Mandarin/Mint Flavor 30 Chewable Tabs

Probiotics for Children & Adults

Gastritis | Helicobacter pylori | Stomach disorders

BioGaiaGastrus® Probiotic Chewable Tablets are a simple, natural, safe and easy way to restore and maintain a healthy microbial balance in the gastrointestinal tract, reduce gastrointestinal inflammation as well as treat functional gastrointestinal disorders. Helicobacter pylori.

Specially designed & clinically proven to prevent & treat stomach related problems

• Unique combination of 2 probiotic strains with complementary properties
• Clinically studied combination
• Unique parallel natural prebiotic action due to their physical structure
• Clinically documented unique dual action, antipathogenic and anti-inflammatory
• Clinically studied combination
• Contains the most studied probiotic strain worldwide in infants and children, one of the three most studied in adults
• Human-isolated strains (of human origin)
• Clinically studied by clinical benefit and age group
• Safe for children and adults, during pregnancy and breastfeeding and for diabetics
• Protected by patents
• It does not contain sugar, lactose, gluten, milk protein
• The first probiotic in the world, specially designed for the treatment of H. pylori eradication and for the treatment of gastric disorders.

For children over 3 years and adults.

Contains the unique probiotic strains Limosilactobacillus reuteri ATCC PTA 6475 (former name Lactobacillus reuteri Protectis®) + Limosilactobacillus reuteri ATCC PTA 6475

• Human-isolated strains (of human origin)
• Unique combination of 2 probiotic strains with common and complementary properties
• Double unique action, antipathogenic and anti-inflammatory
• Clinically studied combination
• Clinically studied by clinical benefit and age group
• Safe for children and adults, during pregnancy and breastfeeding and for diabetics

This biofilm:

a) Protects the probiotic strain which surrounds, from other microorganisms, antibiotics, toxic compounds, osmotics
b) While for the body. Inhibits the adhesion of pathogens to the intestinal epithelium. Supports the symbiotic microflora acting as a prebiotic (food). Regulates the immune system by activating T regulatory cells and increasing anti-inflammatory cytokines

That is, we have a probiotic that also has prebiotic properties. By nature!

USE

Gastritis Prevention & Treatment:

1 tablet daily

Helicobacter pylori eradication & gastrointestinal disorders from antibiotics (diarrhea, abdominal pain, flatulence) | Prevention & Treatment:

1 tablet daily during eradication treatment
1 tablet daily for 2-3 weeks after eradication treatment
Stomach upset (indigestion, bloating, stomach ache, reductions, etc.) | Treatment:

1 - 2 tablets daily or according to individual needs

• Scientifically proven to reduce levels of inflammation, such as gastritis (reduction of gastrin-17 and TNF-α).
• Scientifically proven to reduce the symptoms and side effects from taking strong antibiotic treatment and taking antibiotics for a long time.
• Scientifically proven to reduce dysbiosis caused by taking antibiotics and proton pump inhibitors (PPIs / prazoles).
• Scientifically proven to increase the rate of gastric emptying
• Scientifically proven to reduce the side effects of the pylorus heliobaltridium eradication treatment, increase its eradication rate and improve patient compliance with treatment.
• Clinically proven to improve digestive health and function.
• Absolutely safe.
• Simple dosing regimen (1 tablet / day).

BioGaia Gastrus® chewable tablets contain the clinically studied combination of two probiotic strains, L.reuteri Protectis® and L.reuteri ATCC PTA 6475. L.reuteri Protectis® (L.reuteri DSM 17938) is the proprietary probiotic bacterium of company Bio Sweden, originally isolated in breast milk, is the most studied probiotic in the world in infants and children and one of the three most studied in adults. Its safety and effectiveness have been proven in 217 clinical trials and 180 publications in scientific journals (last updated: January 2020).

L.reuteri Protectis® and L.reuteri ATCC PTA 6475 fully meet the requirements of the WHO. for probiotics. An in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a five-day period showed that L. reuteri Protectis® was one of only three surviving strains. This fact was confirmed in vivo, when taken by healthy people led to significant colonization of the stomach, duodenum and ileum.

L. reuteri Protectis® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function.

It is still the only probiotic that produces the antimicrobial substance ruterin against pathogenic microorganisms, so it has a unique antipathogenic action which is ideally complemented by L.reuteri ATCC PTA 6475 which combines its outstanding property to survive in its hostile environment in the environment. more than 3 hours and offer its clinically proven anti-inflammatory action.

BioGaia AB

BioGaia AB is a Swedish biotechnology company and world leader in probiotics, with a strong innovation profile, over 30 years of experience and expertise.

To date, BioGaia AB holds more than 550 patents, a commercial presence in more than 100 countries and a physical presence in Europe, USA, China and Japan.

BioGaia's vision is to improve human health by offering probiotic products that are clinically proven and proven to be safe and effective by clinical benefit and age group.

To date (2/2020) BioGaia AB has completed more than 217 clinical trials in infants, children and adults and has proven the safety and effectiveness of its probiotic products in various disorders.